Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EWG | ISIN: US79400X4043 | Ticker-Symbol: FP10
NASDAQ
05.06.25 | 19:26
0,751 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SALARIUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SALARIUS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur SALARIUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SALARIUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
14.05.Salarius Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
25.04.Salarius Pharmaceuticals, Inc. - 8-K, Current Report1
16.04.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board13
28.03.Salarius Pharmaceuticals, Inc. - 8-K, Current Report1
26.03.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses162CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate...
► Artikel lesen
24.03.Salarius Pharmaceuticals GAAP EPS of -$5.791
24.03.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update530Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating...
► Artikel lesen
21.03.Salarius Pharmaceuticals, Inc. - 10-K, Annual Report2
11.03.Salarius Pharmaceuticals, Inc. - 8-K, Current Report-
03.02.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers118HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating...
► Artikel lesen
21.01.Salarius Pharmaceuticals, Inc. - S-1, General form for registration of securities-
13.01.Salarius Pharmaceuticals Announces Merger With Decoy Therapeutics To Advance Cancer-
13.01.Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge2
13.01.Salarius Pharmaceuticals and Decoy Therapeutics announce merger6
13.01.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement307Decoy's proprietary IMP3ACT peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding...
► Artikel lesen
13.01.Salarius Pharmaceuticals, Inc. - 8-K, Current Report6
23.12.24Salarius Pharmaceuticals, Inc. - 8-K, Current Report-
16.12.24Salarius Pharmaceuticals, Inc. - S-1, General form for registration of securities-
12.12.24Salarius Pharmaceuticals, Inc. - 8-K, Current Report-
17.06.24XFRA FP10: AUSSETZUNG/SUSPENSION254DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSALARIUS PHARMA....
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1